e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Respiratory manifestations of systemic disease: a holistic approach
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient
A. Hasan, T.L.N. Swamy, R. Ram (Hyderabad, India)
Source:
Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach
Session:
Respiratory manifestations of systemic disease: a holistic approach
Session type:
Thematic Poster Session
Number:
596
Disease area:
Interstitial lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Hasan, T.L.N. Swamy, R. Ram (Hyderabad, India). Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient. Eur Respir J 2012; 40: Suppl. 56, 596
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Aerosolized liposomal cyclosporine A for treatment of progressive allograft dysfunction following lung transplantation
Source: Annual Congress 2013 –Clinical studies in lung transplantation
Year: 2013
A case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression?
Source: Eur Respir J, 57 (6) 2004354; 10.1183/13993003.04354-2020
Year: 2021
Mycophenolate mofetil and azathioprine in chronic hypersensitivity pneumonitis
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Hepatic veno-occlusive disease due to tacrolimus in a single-lung transplant patient
Source: Eur Respir J 2006; 27: 1066-1068
Year: 2006
Impact of mycophenolate mofetil on lung function in chronic hypersensitivity pneumonitis and connective tissue disease related-ILD
Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Year: 2020
Results of switch from mycophenolate mofetil to azathioprin after lung transplantation
Source: Eur Respir J 2004; 24: Suppl. 48, 178s
Year: 2004
Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids
Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Year: 2009
Safety and effectiveness of mycophenolate mofetil in interstitial lung diseases
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Mycophenolate mofetil reduces alveolar inflammation and acute rejection and improves overall outcome after lung transplantation
Source: Eur Respir J 2006; 28: Suppl. 50, 724s
Year: 2006
Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans
Source: Eur Respir J 2004; 23: 384-390
Year: 2004
Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 268s
Year: 2005
High-dose acetylcysteine in idiopathic pulmonary fibrosis
Source: ISSN=ISSN 1810-6838, ISBN=, page=358
Year: 2006
Mycophenolate mofetil (MMF) rescue therapy in lung transplantation: results and pharmacokinetics
Source: Eur Respir J 2002; 20: Suppl. 38, 348s
Year: 2002
Pulmonary alveolar proteinosis due to monocytopenia: Lung transplant or haematopoeitic stem cell transplant?
Source: Annual Congress 2012 - Optimising outcomes after lung transplantation
Year: 2012
Pneumocystis jiroveci Pneumonia prophylaxis in patients treated with mycophenolate mofetil for interstitial lung disease
Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends
Year: 2021
Tacrolimus versus cyclosporine for lung transplant recipients in Portugal
Source: Virtual Congress 2020 – Clinical management of lung transplant recipients
Year: 2020
Epoprostenol therapy for primary pulmonary hypertension after rejection of a single donor lung
Source: Eur Respir J 2003; 21: 192-194
Year: 2003
Comparison of post renal transplant tuberculosis cases receiving conventional immunosupressive therapy and mycophenolat mofetil (MMF) and/or tacrolimus (TAC)
Source: Eur Respir J 2003; 22: Suppl. 45, 157s
Year: 2003
Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Can mycophenolate mofetil 15 mg/kg/day attenuate experimental pulmonary fibrosis in rats?
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept